These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21543548)

  • 61. Cardiovascular adverse events associated with smoking-cessation pharmacotherapies.
    Sharma A; Thakar S; Lavie CJ; Garg J; Krishnamoorthy P; Sochor O; Arbab-Zadeh A; Lichstein E
    Curr Cardiol Rep; 2015 Jan; 17(1):554. PubMed ID: 25410148
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Real-World Effectiveness of Pharmaceutical Smoking Cessation Aids: Time-Varying Effects.
    Chaiton M; Diemert LM; Bondy SJ; Cohen JE; Fung MD; Zhang BR; Ferrence RG
    Nicotine Tob Res; 2020 Apr; 22(4):506-511. PubMed ID: 30260455
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model.
    Knight C; Howard P; Baker CL; Marton JP
    Value Health; 2010; 13(2):209-14. PubMed ID: 19912599
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the "real world".
    Kotz D; Brown J; West R
    BMC Public Health; 2014 Nov; 14():1163. PubMed ID: 25392075
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Very low rate and light smokers: smoking patterns and cessation-related behaviour in England, 2006-11.
    Kotz D; Fidler J; West R
    Addiction; 2012 May; 107(5):995-1002. PubMed ID: 22126678
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Trends in Use of Medications for Smoking Cessation in Medicare, 2007-2012.
    Jarlenski M; Hyon Baik S; Zhang Y
    Am J Prev Med; 2016 Sep; 51(3):301-8. PubMed ID: 27036506
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In smokers with COPD, neither varenicline nor bupropion was linked to increased CV or neuropsychiatric risk vs NRT.
    Kress CM; Obi NU; Prochazka AV
    Ann Intern Med; 2017 Sep; 167(6):JC31. PubMed ID: 28975321
    [No Abstract]   [Full Text] [Related]  

  • 68. Sentiment analysis to determine the impact of online messages on smokers' choices to use varenicline.
    Cobb NK; Mays D; Graham AL
    J Natl Cancer Inst Monogr; 2013 Dec; 2013(47):224-30. PubMed ID: 24395996
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adherence to varenicline in the COMPASS smoking cessation intervention trial.
    Catz SL; Jack LM; McClure JB; Javitz HS; Deprey M; Zbikowski SM; McAfee T; Richards J; Swan GE
    Nicotine Tob Res; 2011 May; 13(5):361-8. PubMed ID: 21350041
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Modern medical support for smoking cessation].
    Hering T
    Internist (Berl); 2009 Jan; 50(1):95-100. PubMed ID: 18946639
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Associations between use of pharmacological aids in a smoking cessation attempt and subsequent quitting activity: a population study.
    Ferguson SG; Brown J; Frandsen M; West R
    Addiction; 2015 Mar; 110(3):513-8. PubMed ID: 25393225
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-Effectiveness Analysis of Varenicline Versus Currently Funded Smoking Cessation Strategies in Brazil.
    Fernandes RRA; Seixas BV; Szklo AS; Guerra RL; Barufaldi LA; de Albuquerque RCR; de Mello Vianna CM
    Value Health Reg Issues; 2022; 27():25-31. PubMed ID: 34784545
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-Effectiveness Analysis of Smoking Cessation Interventions With Behavioral Support: A Study Based on the Benefits of Smoking Cessation on Outcomes (BENESCO) Model.
    Park SK; Kang DW; Lee EK
    Nicotine Tob Res; 2022 Nov; 24(12):2011-2017. PubMed ID: 35862219
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacovigilance Assessment of Cardiac Implications of Nicotine Replacement Therapy Among Smokers.
    Olawuyi O; Mathieson K
    Curr Drug Saf; 2020; 15(3):173-180. PubMed ID: 32525783
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders.
    Taylor GMJ; Itani T; Thomas KH; Rai D; Jones T; Windmeijer F; Martin RM; Munafò MR; Davies NM; Taylor AE
    Nicotine Tob Res; 2020 Jan; 22(1):48-57. PubMed ID: 31289809
    [TBL] [Abstract][Full Text] [Related]  

  • 76. How do patients and staff in an opioid agonist treatment service view smoking cessation medications and e-cigarettes?
    Lobbe C; Bahnisch J; Lin C; Demirkol A; Murnion B
    Drug Alcohol Rev; 2023 Jul; 42(5):1092-1103. PubMed ID: 36877583
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nicotine replacement therapy and other interventions for pregnant smokers: Pregnancy Risk Assessment Monitoring System, 2009-2010.
    Kapaya M; Tong V; Ding H
    Prev Med; 2015 Sep; 78():92-100. PubMed ID: 26190366
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Use of stop-smoking medications in the United States before and after the introduction of varenicline.
    Kasza KA; Cummings KM; Carpenter MJ; Cornelius ME; Hyland AJ; Fong GT
    Addiction; 2015 Feb; 110(2):346-55. PubMed ID: 25331778
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Repeating the same mistake.
    Prescrire Int; 2014 Sep; 23(152):200. PubMed ID: 25325112
    [No Abstract]   [Full Text] [Related]  

  • 80. Varenicline may reduce negative effect while aiding smoking cessation.
    Hays JT
    Evid Based Med; 2014 Feb; 19(1):23. PubMed ID: 23990527
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.